Asset Details
Do you wish to reserve the book?
Relationship between HBsAg/HBV DNA and prognosis in patients with HBV-related hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Relationship between HBsAg/HBV DNA and prognosis in patients with HBV-related hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors
Do you wish to request the book?
Relationship between HBsAg/HBV DNA and prognosis in patients with HBV-related hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Relationship between HBsAg/HBV DNA and prognosis in patients with HBV-related hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors
2025
Overview
Blocking the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) axis could reverse the immune tolerance in the liver microenvironment of hepatocellular carcinoma (HCC). We investigated the efficacy and the safety of PD-1/PD-L1 inhibitors and the possibility of hepatitis B surface antigen (HBsAg) or hepatitis B virus (HBV) DNA levels as prognostic biomarkers in patients with HBV-related HCC.
A retrospective study.
We retrospectively analyzed patients with HBV-related HCC and positive quantitative HBsAg (qHBsAg) who received PD-1/PD-L1 inhibitor therapy at least once. The primary endpoints were overall survival (OS) and objective response rate (ORR), with the secondary endpoint being disease control rate (DCR). Cox regression models were used to illustrate the association of patient characteristics with survival.
A total of 235 patients with HBV-related HCC were included in this study. The median OS for all patients was 20.9 months. The ORR and DCR were 15.7% and 70.6%, respectively. Baseline HBV DNA levels were associated with DCR (
= 0.004). Patients in the qHBsAg-response group in the fourth week had a longer OS after PD-1/PD-L1 inhibitor treatment compared to those in the qHBsAg nonresponse group (29.1 months vs 14.9 months,
= 0.04). Multivariate Cox regression analysis suggested that positive baseline HBV DNA (adjusted hazard ratio (aHR) = 2.6,
= 0.04) and qHBsAg nonresponse at week 4 after PD-1/PD-L1inhibitor therapy (aHR = 2.2,
= 0.04) were independent risk factors for survival.
PD-1/PD-L1 inhibitor therapy in patients with HBV-related HCC showed better efficacy and safety. Negative HBV DNA and a short-term decline in qHBsAg from baseline were associated with superior survival prognosis.
Publisher
SAGE Publishing
We currently cannot retrieve any items related to this title. Kindly check back at a later time.